Amgen

Cartography Biosciences Expands Leadership Team with Appointment of Dan Rock, Ph.D., as Chief Scientific Officer to Advance Novel Oncology Programs into Clinic

Retrieved on: 
Wednesday, February 7, 2024
Oncology, Health, Research, Pharmaceutical, Science, Biotechnology, Washington State University, Neoplasm, Knowledge, Metabolism, Therapy, Safety, Patient, CB21, Publication, Drug discovery, Spacecraft, University, University of Northern Colorado, Amgen, Pharmaceutical industry

Cartography Biosciences , an oncology company advancing a pipeline of antibody therapeutics that more precisely target tumors, today announced the appointment of Dan Rock, Ph.D., as Chief Scientific Officer.

Key Points: 
  • Cartography Biosciences , an oncology company advancing a pipeline of antibody therapeutics that more precisely target tumors, today announced the appointment of Dan Rock, Ph.D., as Chief Scientific Officer.
  • In this role, Dr. Rock will be responsible for guiding the company’s scientific strategy and leading efforts to advance Cartography’s internal programs into the clinic.
  • “As Cartography moves into the next phase of development focused on advancing our internal pipeline discovered from our Atlas platform, we are thrilled to welcome Dan to the team.
  • “I’m honored to be joining a team at the forefront of innovation and I look forward to leading the team as Chief Scientific Officer in the pursuit of better treatment options for patients with cancer.”

EQS-News: Abivax appoints Ana Sharma as Vice President, Global Head of Quality

Retrieved on: 
Wednesday, February 7, 2024
Biostatistics, Research, Novartis, GxP, Therapy, Gastroenterology, Patient, Patient safety, Boston University, Public health, Euronext Paris, Epidemiology, Dana–Farber Cancer Institute, Amgen, Management

Abivax appoints Ana Sharma as Vice President, Global Head of Quality

Key Points: 
  • Abivax appoints Ana Sharma as Vice President, Global Head of Quality
    The issuer is solely responsible for the content of this announcement.
  • Abivax appoints Ana Sharma as Vice President, Global Head of Quality
    PARIS, France, February 7, 2024, 8:30 a.m. CET – Abivax SA (Euronext Paris and Nasdaq: ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases, today announced the appointment of Ana Sharma as Vice President, Global Head of Quality.
  • Ms. Sharma brings over 20 years of experience in the biopharmaceutical industry and has a strong track record in quality and GxP compliance.
  • If approved, it would be available to many patients who are in need of safe and long-term efficacious therapeutic options for chronic inflammatory diseases.”
    Ana Sharma joined Abivax from Takeda, where she held the position of Vice President, Global Head of Research and Development Clinical Quality Assurance.

Abivax appoints Ana Sharma as Vice President, Global Head of Quality

Retrieved on: 
Wednesday, February 7, 2024
Biostatistics, Research, Novartis, GxP, Therapy, Gastroenterology, Patient, Patient safety, Boston University, Public health, Euronext Paris, Epidemiology, Dana–Farber Cancer Institute, Amgen

Abivax appoints Ana Sharma as Vice President, Global Head of Quality

Key Points: 
  • Abivax appoints Ana Sharma as Vice President, Global Head of Quality
    PARIS, France, February 7, 2024, 8:30 a.m. CET – Abivax SA (Euronext Paris and Nasdaq: ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases, today announced the appointment of Ana Sharma as Vice President, Global Head of Quality.
  • Ms. Sharma brings over 20 years of experience in the biopharmaceutical industry and has a strong track record in quality and GxP compliance.
  • Marc de Garidel, Chief Executive Officer of Abivax, says: “I am glad Ana joins our team with her extensive experience in research and development quality assurance in the biopharmaceutical sector.
  • If approved, it would be available to many patients who are in need of safe and long-term efficacious therapeutic options for chronic inflammatory diseases.”
    Ana Sharma joined Abivax from Takeda, where she held the position of Vice President, Global Head of Research and Development Clinical Quality Assurance.

TScan Therapeutics Expands Clinical Team with the Appointment of Dawn Pinchasik, M.D., M.S., as Vice President, Clinical Development

Retrieved on: 
Tuesday, February 6, 2024
Rubius, Drug, Translational research, Patient, Pediatrics, Medicine, Therapy, University, TCR, Acquisition, Amgen, Cancer, Onyx Pharmaceuticals, Nursing

Dr. Pinchasik brings to TScan over a decade of experience in clinical development across the pharmaceutical and biotechnology industry.

Key Points: 
  • Dr. Pinchasik brings to TScan over a decade of experience in clinical development across the pharmaceutical and biotechnology industry.
  • “We are pleased to welcome Dawn to TScan at such an exciting time in the Company’s evolution,” said Debora Barton, M.D., Chief Medical Officer.
  • “Her expertise in cell and gene therapy clinical development and experience with regulatory interactions, most recently at ElevateBio, will be crucial as we advance our clinical-stage pipeline across heme malignancies and solid tumors.
  • from Drexel University College of Medicine, and an M.S., Clinical and Translational Research, from the University of Cincinnati.

Global DLL3 Targeted Therapies Market Opportunities & Clinical Trials Insight 2024: Insights On 10 Current & Potential Proprietary Platforms, Company, Indication & Phase for 15 Drugs, and 14 Companies - ResearchAndMarkets.com

Retrieved on: 
Thursday, February 1, 2024
Science, Other Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, Clinical Trials, Carcinoma, Ligand, SCLC, Indication, Novartis, History, Therapy, Chugai Pharmaceutical Co., FDA, DLL3, AbbVie, Boehringer Ingelheim, Malignancy, Bladder cancer, Amgen, Cancer, Bi-specific T-cell engager, Growth, Pharmaceutical industry

The "Global DLL3 Targeted Therapies Market Opportunities & Clinical Trials Insight 2024" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global DLL3 Targeted Therapies Market Opportunities & Clinical Trials Insight 2024" report has been added to ResearchAndMarkets.com's offering.
  • Global DLL3 Targeted Therapies Market Opportunities & Clinical Trials Insight 2024 Report Finding & Highlights:
    Insight On Current & Potential DLL3 Targeted Therapies Proprietary Platforms: > 10 Platform
    DLL3 Targeted Drugs Clinical Trials Insight By Company, Indication & Phase: > 15 Drugs
    Insight On Companies Involved In R&D Of DLL3 Targeted Therapies: 14 Companies
    In recent years, the discovery of Delta Like Ligand 3 (DLL3) as a therapeutic cancer target has emerged as key defining moment in the targeted therapy landscape.
  • Stemcentrx, now a subsidiary of AbbVie, led the development of Rovalpituzumab tesirine (Rova-T), which was a pioneering endeavor in the field of DLL3 targeted therapies.
  • The dynamic evolution of DLL3 targeted therapies is characterized by a wide range of candidates in clinical trials, extending far beyond Rovalpituzumab conjugates.

Care Access Becomes Newest Member of the National Lipid Association Industry Council, Joining Novartis, Amgen, and Other Cardiovascular Health Leaders

Retrieved on: 
Wednesday, January 31, 2024
Research, Surgery, Clinical Trials, Cardiology, Practice Management, Other Health, Health, General Health, Science, Principal, Stenosis, Physician, Novartis, National Lipid Association, Regeneron Pharmaceuticals, Clinical trial, Access, Cardiovascular disease, Patient, Esperion Therapeutics, Entrepreneurship, Therapy, Risk, NLA, Coronary artery disease, Learning, Stroke, Medicine, Amgen, Esperies, JD, Pharmaceutical industry

Care Access, a global clinical research company helping to accelerate the future of medicine, is joining the National Lipid Association (NLA) Industry Council.

Key Points: 
  • Care Access, a global clinical research company helping to accelerate the future of medicine, is joining the National Lipid Association (NLA) Industry Council.
  • The collaboration aims to enable more community-based lipidologists to participate in clinical research and create access to cardiometabolic trials for their patients.
  • The NLA represents doctors and other experts from around the country who treat patients at the highest risks of cardiovascular disease.
  • "At Care Access, we are committed to facilitating clinical trial access for patients from all walks of life," said Ahmad Namvargolian, Care Access CEO and Co-Founder.

Madrigal Pharmaceuticals Announces Additions to Its Leadership Team

Retrieved on: 
Monday, January 29, 2024
Senior, Engineering, Rensselaer Polytechnic Institute, Amgen, Therapy, Central Connecticut State University, Pratt & Whitney, Fibrosis, Divisional patent application, Loyola University, Human resources, Entrepreneurship, Business, Manufacturing engineering, M.B.A, GE HealthCare, University, Cancer, Organization, Fatty liver disease, Duke University, Frazier Healthcare Partners, Horizon Therapeutics, Johnson & Johnson, NASH, Officer (armed forces), BASF, Institutional Investor, Management

“I am delighted to welcome Mark, Clint and Tina to the team,” said Bill Sibold, Chief Executive Officer of Madrigal.

Key Points: 
  • “I am delighted to welcome Mark, Clint and Tina to the team,” said Bill Sibold, Chief Executive Officer of Madrigal.
  • “As we prepare for a first-to-market launch of resmetirom in NASH with significant fibrosis, we are also building a foundation for enduring leadership.
  • Prior to Kenvue, he was the Senior Vice President Human Resources, North America, Sanofi, from 2016-2022, serving as a member of the Sanofi Global HR Leadership Team.
  • Tina Ventura brings nearly 25 years of experience in global health care investor relations and communications to Madrigal.

DiaMedica Therapeutics Appoints Dr. Lorianne Masuoka as Chief Medical Officer

Retrieved on: 
Monday, January 22, 2024
Biotechnology, Health, Pharmaceutical, Clinical Trials, Cardiology, Psychiatry, Cubist Pharmaceuticals, Amgen, Patient, Therapy, Employment, Neurology, Biostatistics, Data management, DMAC, Pharmacovigilance, Stroke, University, NKTR, Yale University, Acquisition, Epilepsy, Nektar Therapeutics, DSM-IV codes, Pharmaceutical industry

DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and cardio-renal disease, announced today the appointment of Lorianne Masuoka, M.D.

Key Points: 
  • DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and cardio-renal disease, announced today the appointment of Lorianne Masuoka, M.D.
  • as Chief Medical Officer.
  • “We are delighted to have Lorianne join our executive leadership team,” said Rick Pauls, DiaMedica’s President and Chief Executive Officer.
  • Dr. Masuoka received her medical degree from the University of California, Davis, where she also completed her residency in neurology.

Advanced Medicine Partners Launches to Set New Standard for Manufacturing and Testing Advanced Medicines

Retrieved on: 
Wednesday, January 17, 2024
Health, Genetics, Other Health, General Health, Research, Science, Pharmaceutical, CMC, Patient, Amgen, GLP, Biotechnology, AAV, Novartis, GMP, Medicine, IND, Therapy, ARCH Venture Partners, Novartis Gene Therapies, Pharmaceutical industry

“Advanced Medicine Partners is a science- and mission-driven organization made up of one of the most experienced genetic medicines teams in the industry, and we are driven to deliver products and services that aim to set a new standard in the manufacturing and testing of innovative therapies,” said Andrew Knudten, CEO of Advanced Medicine Partners.

Key Points: 
  • “Advanced Medicine Partners is a science- and mission-driven organization made up of one of the most experienced genetic medicines teams in the industry, and we are driven to deliver products and services that aim to set a new standard in the manufacturing and testing of innovative therapies,” said Andrew Knudten, CEO of Advanced Medicine Partners.
  • Advanced Medicine Partners’ process has been used with multiple genes of interest as well as multiple wild-type AAV serotypes and engineered capsids.
  • Advanced Medicine Partners brings extensive operational experience from Jaguar Gene Therapy and other biotechnology companies, including AveXis, Novartis and Amgen.
  • In addition to Advanced Medicine Partners’ manufacturing and analytical testing capabilities, the company offers GMP tech transfer capabilities and virtual CMC support.

Regenerative Medicine Market Worth $49.0 Billion | MarketsandMarkets™.

Retrieved on: 
Friday, January 26, 2024
Conditional sentence, Artificial intelligence, Dermatology, Market development, HSCT, Regenerative medicine, Research, Neurology, Pulse, Ophthalmology, Amgen, Smith & Nephew, Novartis, Cancer, Integration, Gilead Sciences, Investment, Tissue engineering, Takeda Pharmaceutical Company, Biogen, Transplant, Prevalence, DSM-IV codes, Growth, Veterinary medicine

The cell therapy segment accounted for the largest share of the regenerative medicine market in 2022.

Key Points: 
  • The cell therapy segment accounted for the largest share of the regenerative medicine market in 2022.
  • In 2022, the musculoskeletal disorders segment accounted for the largest share of the global regenerative medicine market.
  • •  Market Development: Comprehensive information about lucrative markets – the report analyses the regenerative medicine market across varied regions.
  • •  Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the regenerative medicine market.